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Glucocorticoids (GCs) are used in the treatment of systemic lupus erythematous (SLE) and 
myositis to control disease symptoms, but can have significant adverse effects. While 
physicians recognize some of these effects, little data exists surrounding the perspectives of 
patients with SLE and myositis on GC effects. The objective of this study is to understand the 




Patients with SLE or myositis were asked to participate in five nominal groups where 
demographic information and a quality of life questionnaire was completed. Patients were 
asked two open-ended questions on 1) benefit and 2) harms related to GC use. Nominal 
Group Technique (NGT), a highly structured consensus method in which responses are 




Of 206 patients who were approached, 21 patients participated, 17 with SLE and 4 with 
myositis, predominantly women with >20 years of steroid use. The domains ranked highest 
for GC benefits were disease control (55 votes), fast-acting (30 votes), increases energy (10 
votes) and pain relief (10 votes). The highest ranked negative effects were bone loss (38 
votes) and weight gain (16 votes); psychological effects and damaged internal organs each 
received 12 votes.  
 
Conclusions:  
The top ranked GC effects-both benefits and harms-among patients with SLE and myositis 
are consistent with the top domains associated with GC use in other inflammatory diseases. 
This study supports the development of a comprehensive patient reported outcome 





Systemic glucocorticoids (GCs) are widely used to treat many inflammatory 
diseases, and are a mainstay in the therapy of systemic lupus erythematosus (SLE) 
and the inflammatory myopathies.  1-4 While GCs are generally effective at 
controlling disease activity, they additionally have both positive and negative 
impacts upon health and quality of life.  5-9 Some adverse events (AEs) – such as 
osteoporosis, weight gain, and diabetes are well recognized and can be measured by 
physicians. However, there may be other effects of GC therapy that concern patients 
such as skin thinning, sleep disturbance and anxiety that have traditionally not been 
as well quantified by physicians.  10 Previous research by the European League 
Against Rheumatism (EULAR) and the Outcome Measures in Rheumatology 
(OMERACT) taskforces have recognized a need to systematically quantify the effects 
of GCs across patient groups. The EULAR group on GC effects has published two 
systematic literature reviews,  11,12 and has developed the Glucocorticoid Toxicity 
Index (GTI), but the GTI does not include patients’ perspectives.  13 Therefore, it is 
possible that the GTI fails to capture some of the effects of GCs that are of 
importance to patients. Discordance between physicians and patients is common in 
healthcare and suggests that patients may also perceive and prioritize GC effects 
very differently from providers.  14 Ultimately, the development of a patient reported 
outcome (PRO) that specifically addresses the positive and negative effects of GCs 
on patients’ health, quality of life and overall lived experience, would complement 
the GTI and aid physicians in assessing treatment effect with GCs alone but also in 
comparison to other steroid-sparing therapies.  
 
As new therapies are developed, their efficacy and adverse effects are compared to 
those of ‘standard of care’ medications. For this reason, the OMERACT GC special 
interest group (SIG) met in 2016 and 2018 to set a research agenda with the goal to 
work towards creating a PRO that effectively quantifies all systemic GC related 
effects and AEs across inflammatory rheumatic diseases. 10,15 At present, studies 
have identified the impacts of GCs in patients with rheumatoid arthritis (RA), 
Polymyalgia rheumatic (PMR), giant cell arteritis (GCA) and ANCA-associated 
vasculitis.  10,16 These studies show that weight gain, sleep disturbance, thin 
skin/easy bruising, and upset stomach are among the most worrisome effects to 
patients with these diseases. Yet, the effects of GCs in patients with SLE and myositis 
from the patients’ perspective have not been studied.  
 
The aim of this study, was to utilize nominal group technique (NGT) to identify and 
prioritize the effects of GCs, both beneficial and harmful, which are of importance to 








Individuals over the age of 18 with a diagnosis of SLE or an inflammatory myopathy 
and meeting American College of Rheumatology (ACR) classification criteria or 
Bohan and Peter criteria, respectively were recruited from rheumatology practices 
at the Hospital for Special Surgery, New York, NY. In addition to meeting 
classification criteria, participants had to be currently or previously taken systemic 
GCs. Those with overlapping rheumatic diseases were not excluded. Individuals 
were identified by their rheumatologists, contacted by telephone or e-mail and 
invited to participate. The participants received a payment in consideration of their 
time, parking or transportation was reimbursed, and snacks were served during the 
sessions. 
 
Prior to the start of the nominal group, participants completed a questionnaire to 
capture demographic data and to determine their exposure to GCs. The participants 
also answered the Patient-Reported Outcomes Measurement Information System 
(PROMIS) Global-10 questionnaire, a validated tool used to assess general domains 
of health.  17 The questionnaire is comprised of 10 questions and scores are 
summarized as the global mental health score and global physical health score. 
Scores are reported as percentiles, with higher scores indicating better status.  
 
Description of NGT 
NGT is a variant of the traditional focus group and is an effective method for 
studying specific questions in a detailed manner.  18 This method has been used to 
study the patients’ perspective across many different diseases.  19-27 NGT is a 
consensus building method that can be used to efficiently establish and rank 
important effects through responses to open ended questions. The participants list, 
discuss, and then prioritize the responses during the sessions, ultimately voting on 
the nominated responses, producing a ranked list.  
 
The nominal group (NG) discussions lasted approximately two hours, and two 
questions were answered, approximately one hour per question. An experienced 
leader (SG) and assistant (SM) led the groups. The two questions were selected for 
the patient groups after discussion and informal testing by the investigators. After 
introductions, the group leader explained the focus of the session and then 
described the process for the participants. 
 
The first question assessed the benefits of GCs from the patients’ perspective,  1) “In 
addition to the impacts on your illness, what effects are the most important to 
patients who are taking steroids?” . The second question inquired about potential 
harms of GC use,  2) “What do you think are the most significant unwanted effects or 
harm from taking steroids?”.  The questions were discussed sequentially, one at a 
time. After clarifying any questions from the group, the patients were asked to 
independently write down as many responses as possible to the question from their 
own perspective. Then, in a round-robin fashion, the responses were reported and 
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recorded on a flip board. As a group, the responses were expanded upon through 
discussion and, when necessary, collapsed when responses addressed the same 
domains. Finally, each patient recorded the three domains on an index card that he 
or she thought were the most significant, taking into consideration the perspective 
of all patients with SLE and/or an inflammatory myopathy and were each given 6 
votes to distribute among the nominated responses. The top response was given 
three votes, the next two votes and the last one vote. The votes from all participants 
were subsequently tabulated, establishing the rank order.  The project was 
completed when thematic saturation was achieved. 
 
Statistical Analysis  
Baseline data was analyzed using descriptive statistics. Steroid dosage was 
converted to prednisone equivalent. PROMIS Global-10 scores were calculated using 
a publicly available online calculator http://orthotoolkit.com/promis-10/, and were 
reported as global physical and mental health scores.  28 
 
The study was approved by the Hospital for Special Surgery’s Institutional Review 




We identified 206 individuals, and called/e-mailed 158 of whom 101 responded and 
48 unable to reach by phone or email. Thirty-five patients were interested in the 
study and a total of 21 patients participated. The groups included 17 patients with a 
diagnosis of SLE and four with myositis who participated in five NG discussions 
from April 9th 2019 to May 9th 2019.  The mean age of all participants was 46.0 years 
(42.5 years for the SLE group and 61.0 years for the myositis group). Nineteen 
participants were female and most patients had experience taking GCs for more 
than 20 years, with 13 participants currently remaining on oral GCs. Those with SLE 
were on a mean current prednisone equivalent dose of 8.2 mg while those with 
myositis 2.4 mg.  Sixteen patients with SLE and three with myositis reported being 
afraid of long-term side effects and two participants reported that they enjoyed 
taking GCs. Overall if given the option to increase, decrease or to not change their 
dose of steroids, one reported that they would increase their dose, 15 would 
decrease their dose and 5 would not change their dose. (Table 1) The mean ±SD 
PROMIS10 physical health score for the SLE group was 57.6±11.7 and 60.0±7.1 for 
the myositis group. The mental health scores were 57.4 ±15.1 and 62.5±15.5, 
respectively. (Table 1) 
 
Summary of votes: 
Question 1 “In addition to the impacts on your illness, what (beneficial) effects are the 
most important to patients who are taking steroids?” 
 
The first question considered the benefits of GCs, receiving a total of 126 votes. The 
domains voted on for the most important benefits of GCs were: 1. controls disease 
and symptoms (55 votes), 2. works fast (30 votes), 3. increases energy (10 votes) 
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and 4. relieves pain (10 votes). Additional items included: 5. thinking clearer (4 
votes), increased appetite (1 vote), affordable (3 votes) and 9 votes from the first 
group who listed harms not benefits. The least voted on domain was: 6. flexibility of 
use (4 votes).  
      
Question 2, “What do you think are the most significant unwanted effects or harm 
from taking steroids?”  
 
This question received 126 votes. The most highly ranked domains were: 1. bone 
loss (38 votes), 2. weight gain (16 votes), 3. psychological effects (12 votes), and 4.  
damaged internal organs (12 votes). Additional domains were: 5. other (10 votes), 6. 
dependence (9 votes), 7. physical appearance (7 votes), 8. sleep disturbance (6 
votes), 9. weakness of muscles and ligaments (6 votes), 10. increased risk of 
infection (6 votes), and 11. eye problems (4 votes).  The following items were voted 
on in the other category: high sugar (2 votes), height (2 votes), teeth problems (2 
votes), skin thinning (1 vote), high cholesterol (1 vote), lack of compatibility with 
other drugs (1 vote) and difficulty concentrating (1 vote).  The full summary scores 
are available in Table 2.  
 
Summary of domains: 
In this study, patients with SLE and myositis ranked GC effects according to the 
importance to them. Most important was the effectiveness of GCs to control the 
symptoms of SLE or myositis. This domain received a total of 55 votes and was 
voted for in three of the five groups. Important disease symptoms that patients 
mentioned were inflammation, morning stiffness, lack of mobility, rashes, flares, and 
low quality of life, all of which were improved by taking GCs. One patient mentioned 
that GCs help her “get through the day,” and without it, “ You can’t go about normal 
activities of the day like brushing your teeth, blow drying your hair and being able 
to work”. Another patient spoke about GCs controlling rashes. She said, “When I 
flare up I break out in rashes. As soon as I take it or when my doctor increases the 
prednisone, within 24 hours the rash is gone.” A third patient said that GCs “kept me 
stable so I can have a full time job. I can be in my 20s in New York, can travel and I 
don’t think I could do any of those things without it.”  
 
The speed of onset of GCs received the second highest number of votes. Three of five 
groups mentioned that GCs “working fast” as an item of importance, with a total of 
27 votes. Patients who voted on this domain said that GCs lead to “fast symptom 
relief” and “it helps cure the immediate medical diagnosis”. One patient said, “My 
foot will be swollen and 20 minutes after taking it I can get up”.  Another patient 
said that GCs sped up the healing process itself. She said, “Whatever I got pertaining 
to lupus – it made the healing process faster”. 
 
Feeling energetic and pain relief were the next most important effects voted on and 
they each received 10 votes. Both domains were voted for in three of the five 
groups. Under the energy domain, patients mentioned having an “increase of energy 
level” as one of the most important effects of GCs.  Patients who voted on this 
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domain said, “It increases the ability to move about because of the energy.” Another 
patient mentioned that GCs “helps me feel stronger physically. You don’t feel old – 
sometimes I do and when you take it that feeling goes away.”  For pain relief 
patients mentioned a decrease in joint pain and complete elimination of pain.  
 
Patients ranked the flexibility of taking GCs as the domain with the next highest 
importance, with a total of four votes. However, this was only voted on in two of the 
five groups. Under this domain patients described the flexibility as being able to take 
GCs as needed, taking GCs while pregnant and the ability to self-manage their dose, 
increasing and tapering as needed. While patients agreed this was an important 
characteristic of GC use, their experiences with the flexibility of GCs varied. One 
patient was able to stop taking steroids as she wanted and said, “I just didn’t want to 
take it anymore and didn’t have any side effects or anything. I haven’t been on it in 
10 years.” While another patient had more difficulty, and said, “Every time I try to go 
down to 1 mg and try to go off of it, it causes problems or difficulties…every time I 
tried to go down I had to come back up.” 
 
Other items that patients voted on as being important to them were the ability to 
help them think more clearly (four votes), give them an increased appetite (one 
vote), and affordability (three votes). All three of these items were only voted on in 
the third NG. Appendix Table 1 shows the complete list of quotations and votes for 
each NG. 
 
Amongst the most important harmful effects of GCs, bone loss received the most 
votes. This item was voted for in all five NGs and received a total of 31 votes. 
Patients who voted for this category discussed general bone damage, osteoporosis 
and avascular necrosis (AVN).  A patient with AVN said, “For me it’s AVN. I’m 27 and 
I’m asking why do I have this and it’s because I’ve been taking it (GCs) for 10 years. 
And I go to the gym a lot so what’s going to happen at 65”.  Another patient showed 
a similar fear from bone loss and said, “That’s what makes me not want to take it – 
it’s supposed to make me feel better, but it’s also destroying my bones”. 
 
After bone loss, weight gain was the next most important domain and received 14 
votes.  This domain was mentioned in four of five groups. Besides general weight 
gain, patients also discussed common GC side effects, such as moon face and an 
increase in appetite. One patient also mentioned fat re-distribution with a buffalo 
hump, however this was viewed as a separate category under physical appearance 
and received no votes.  
 
The psychological effects domain received 12 votes and was voted for in three of the 
five groups. Within this domain, patients mentioned moodiness and mood 
instability, depression and anxiety, irritability, and feeling “uncomfortable with 
myself”. For example, one patient said, “My mom would always ask me why are you 




Though patients mentioned feeling a sense of flexibility with GCs in the first 
question, they also voted feeling dependent on the medication as a negative 
consequence in the second question. Dependence received a total of nine votes and 
was voted for in two groups. Within those groups, patients mentioned a danger of 
suddenly stopping GCs, long tapering periods and feeling “addicted” to the 
medication.  
 
The issue of physical appearance received seven votes and was mentioned in three 
of five groups. The items under this domain included a general change in physical 
appearance, excessive hair growth, moon face, and buffalo hump. One patient 
described this issue as, “a big issue for everyone”. She said, “You can hide the stuff 
that’s going on the inside. When it starts to manifest in your physical appearance its 
harder to hide.” 
 
The other domains that received votes under this question include: sleep 
disturbance, muscle and ligament weakness, infection, internal damaged organs, eye 
problems, high blood sugar, skin thinning, high cholesterol and blood pressure, 
teeth problems, lack of compatibility with other drugs and difficulty concentrating. 
It is important to note that 3 groups voted on internal damaged organs, two of the 
groups voted specifically on stomach irritation. The third group voted generally on 
internal damaged organs and when asked to expand upon the item, mentioned 
kidney damage. One patient who began GCs at age four mentioned and voted for 
stunted height/growth as an important harmful effect of GCs. Appendix Table 2 
includes a complete list of quotations and votes for each domain voted on in 
question two.  
 
Discussion:  
Amongst patients with SLE and the inflammatory myopathies, the domains with the 
highest number of votes related to the benefits of GCs were the ability to control the 
disease and associated symptoms, the ability of GCs to resolve these symptoms 
quickly, an increase in energy, and pain relief. In contrast, the highest-ranking 
domains for the unwanted or harmful effects were bone loss and damage, weight 
gain, psychological effects, and damaged internal organs (stomach and kidneys).  
 
Overall, this study shows that the most important beneficial and harmful effects of 
GCs on patients with SLE and myositis are similar to those in other inflammatory 
conditions. Previous qualitative studies  10 amongst patients with RA and vasculitis, 
GCA and PMR show that the top benefits of GC use are their ability to effectively 
treat disease symptoms and their ability to provide rapid relief of symptoms. 
However, other studies have reported an increase in energy as a harmful side effect 
of GCs.   29 This is contrary to our study, where patients ranked an increase in energy 
as the third most important benefit. Importantly, when we asked patients to expand 
upon this item, most reported that the increase of energy allowed them to 




More studies have focused and reported on the harmful side effects of GC use in 
patients with inflammatory conditions.  10,16,29 to our results, bone loss, weight gain 
and psychological effects were amongst top unwanted effects of GC use.  Some 
studies  10,16 showed skin thinning and bruising amongst top effects, while this item 
only received 1 vote in our study. This difference could be due to a small number of 
participants. Additionally, within the category of bone loss, several patients in our 
cohort mentioned AVN as a specific issue, which was not specifically mentioned in 
previous studies amongst patients with other rheumatic diseases, likely owing to 
the fact that SLE patients are at higher risk of AVN development than other 
rheumatic diseases. 
 
The study strengths are that all patients included met either SLE or myositis 
classification criteria. Further, to our knowledge, this is the first study using NGT to 
ask patients with lupus and myositis of both the benefits and harms of GCs. The 
weaknesses of this study include a low number of patients, especially in the myositis 
group. Recruiting large amounts of myositis patients for studies is difficult given the 
rarity of the condition itself. However, the patients that were included met either 
myositis or SLE ACR classification criteria, which improves sample homogeneity. 
 
Additionally, NG one only included two participants, who focused exclusively on the 
harms of GCs.  
 
Previous qualitative research performed with patients with SLE by Mathias et al  30 
included concept elicitation of medication effects for SLE symptom domains of 
importance and queried GC dose, but did not address both beneficial and harmful 
effects of GC. Out study specifically addresses GC effects in patients with SLE or 
myositis. Additionally, in a review of patients with SLE by Holloway et al,  31 27 
symptoms and impacts of SLE were identified, but medication effects were again not 
addressed. This study did evaluate the patient-reported outcome of GC effects in SLE 
and myositis patients, which our study attempted to explore.   
 
In conclusion, our results show that the top three most important effects or benefits 
of GCs to patients with SLE and myositis were the GCs’ ability to control the disease 
symptoms, do so in a quick manner and increase energy. The top three most 
harmful effects in this patient population were bone loss, weight gain and 
psychological effects. These effects are similar to benefits and harms across several 
different rheumatic diseases. Thus, clinicians and patients could both benefit from 
the development of a comprehensive patient-reported outcome measure to quantify 
the overall effects of oral GCs.  
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Age, (mean ± SD) 42.5 ± 14.4 61.0 ± 15.5 46.0 ± 15.7 
Sex, Female, n (%) 15 (88.2) 4 (100.0) 19 (90.5) 
Race, n (%) 
White 3 (17.6) 3 (75.0) 6 (28.6) 
Black 8 (47.1) - 8 (30.1) 
Asian 5 (29.4) - 5 (23.8) 
Hispanic 1 (5.9) - 1 (4.8) 
Disease duration, n (%) 
<2 years - 1 (25.0) 1 (4.8) 
2-5 years 1 (5.9) - 1 (4.8) 
5-10 years 7 (41.2) - 7 (33.3) 
10-20 years 4 (23.5) - 4 (19.0) 
> 20 years 5 (29.4) 3 (75.0) 8 (30.1) 
Currently using steroids, Yes n 
(%) 
9 (52.9) 4 (100.0) 13 (61.9) 
Steroid dose*, mg (mean ± SD) 8.2 ± 3.9 2.4 ± 1.0 6.3 ± 4.1 
Duration of steroid use, n (%) 
< 6 months 3(17.6) - 3 (14.3) 
6 months – 1 year 1 (5.9) - 1 (4.8) 
1-5 years 1(5.9) 1 (25.0) 2 (9.5) 
5-10 years 3 (17.6) - 3 (14.3) 
>10 years 9 (52.9) 3 (75.0) 12 (57.1) 
Do steroids help with pain? Yes 
n (%) 
15 (88.2) 4 (100.0) 19 (90.5) 
Are you afraid of long-term 
side effects? Yes n (%) 
16 (94.1) 3 (75.0) 19 (90.5) 
Do you like steroids? Yes, n (%) 2 (11.8) - 2 (9.5) 
If your physician wanted to 
change the dose what would 
you do? n (%) 
Increase 1 (5.9) - 1 (4.8) 
Decrease 12 (70.6) 3 (75.0) 15 (71.4) 
No change 4 (23.5) 1 (25.0) 5 (23.8) 
PROMIS global physical health 57.6 ± 11.7 60.0 ± 7.1 58.1 ± 10.6 
PROMIS global mental health 57.4 ± 15.1 62.5 ± 15.5 58.3 ± 14.6 
* steroid dose reported as prednisone equivalent.  






Table 2. Summary scores for questions 1 and 2 
 
Question 1: In addition to the impacts on your illness, what effects are the 
most important to patients who are taking steroids? 
Domain Total votes 
Controls disease/symptoms  55 
Works fast  30 
Other * 17 
Energy 10 
Pain Relief 10 
Flexibility of use 4 
Question 2: What do you think are the most significant unwanted effects or 
harm from taking steroids? 
Domain Total votes 
Bone loss 38 
Weight gain 16 
Psychological effects  12 
Damaged organs 12 
Other 10 
Dependence  9 
Physical appearance  7 
Sleep disturbance 6 
Weakness 6 
Infection 6 
Eye problems 4 
*Includes 9 votes from group 1 who did not answer the question correctly. 
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Appendix Table 1. Responses to Question 1 “In addition to the impacts on your 




NG #1: 4/9/2019, 3:00 PM. 2 Female. 1 African-American, 1 White. 12 votes* 
F. Other: Insomnia 
 Big issue for me – still is, in general it’s a quick fix and helps with 
symptoms after taking it for a while 
 I’m not rested for periods of time; tend to go into a fatigue syndrome. 
Groggy during the day and not always clear. You’re not in your best mood 
and feel always tired.  
 If don’t sleep – I won’t sleep for days in a row.  
 So exhausted from doing day-to-day things that you have to do.  
 Exhausted or fatigue from lupus gets to you, I need to take Ambien  
2 
F. Other: Avascular Necrosis 
 Have it in both hips, after a whole year I wasn’t getting any better and 
needed a hip replacement.  
2 
F. Other: Acne 
 Feel like going back to being a teenager.  
 In my adolescence I never suffered with acne, come to my 30s and all of a 
sudden it’s like what is going on with my face.  
 Also have complexion changes. My skin is quite different from before to 
now.  
o Changes in skin/facial features.  
 I have a round face, beaver face. My hair and eyebrows started getting 
darker, and I’m thinking this is terrible. 
o Peach fuzz/unwanted hairs 
 For me it shows up on the side of my face. It’s frustrating and comes 
down to affecting physical appearance.  
 I don’t tell anyone, I find that I can’t control most of what goes on, but I 
can control who I tell about it – I don’t like it when it starts affecting your 
physical appearance. 
4 
C. Works fast: 
 Especially when I was really struggling with infusion treatments. I have 
three within a week of 1000.  
 It’s a known evil, but you know it will help.  
o Helps with issues relatively quickly. 
 Helps with other issues that you have too. It controls my asthma – didn’t 
have to use inhaler and helped with allergies  
 Helps with migraines. Your body adjusts, I’m already down to 10 mg a day 
and my headaches are worse, everything comes back but you don’t want to 
go back up. 
3 
F. Other: Can’t stop taking it suddenly 1 
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 Everything is worse off when you suddenly stop taking it  
NG #2: 4/10/2019, 4:30 PM. 2 Female, 1 Male. 3 African American. 18 votes. 
C. Works fast: Made healing process faster 
 Healing from anything. Whatever I got pertaining to lupus – it made the 
healing process faster. Without steroids it would take months to heal from 
a paper cut 
7 
B. Pain Relief: Less joint pain 6 
A. Energy: Increase in energy level 
 For a long time I had a problem with fatigue 
 Feel like I can do almost anything 
 At higher doses keeps me awake at night – harder to fall asleep and stay 
asleep. 
5 
NG #3: 4/29/2019, 4:00 PM. 6 females. 2 white, 2 African American, 2 Asian. 36 votes. 
C. Works fast: 
o Fast symptom relief  
o Helps cure the immediate medical diagnosis 
 Wake up quite a bit to move around due to pain, especially in my upper joints, 
I have a deep sleep when I’m on the steroids.  
 It’s the discomfort that wakes me up. I have other pain medications that I use 
during major flare-ups. 
o High dose works quickly 
 Can get good response with lower doses/shorter courses 
12 
E. Controls disease: Reduces inflammation 11 
F. Other: Think clearer  
 Some days I’m in a fog and during the periods I’m on steroids I can focus 
better 
o Can think better 
4 
A. Energy: 
 Gives you so much energy 
o Increases ability to move about 
 Because of the energy 
3 
B. Pain relief: Takes the pain completely away 
o Pain relief 
o Reduces pain 
2 
F. Other: It gives me an appetite  1 
F. Other: Reasonably cheap, we can afford it. 
 Have to take it for a long time so it could be expensive 
3 
NG #4: 5/7/2019, 4:30PM. 7 females. 2 white, 3 African American, 2 Asian. 42 votes. 
E. Controls disease: Keeps inflammation down. 14 
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 Inflammation in my knees, sometimes my back – I’ll be stuck and can’t do 
anything. After 20 minutes of taking it I can grab something and move. 
o Helps get rid of pain 
o Controls the rashes 
 When I flare up I break out. As soon as I take it or when my doctor increases 
the prednisone, within 24 hours it’s gone. I know I’m having a flare up 
because of my rash and then I start to feel the physical stuff – that’s the only 
good thing about it. 
o Only thing that works to control flares 
 It starts to immediately manifest in pain cycle, shortly followed by fevers. 
That’s what makes it possible for me to have a life. I have arthritis as a 
complication of macrophage syndrome so it’s the only thing that works 
o Controls fevers 
E. Controls disease: Overall increases quality of life.  
 I have a 4 year old and a 5 year old and I’m able to get on the floor with 
them and ride bikes with them, it’s the steroids that allow me to do that 
o Can get through the day 
 Gives you a burst of energy, without it you can’t go about your normal 
activities of the day, brushing your teeth or drying your hair 
 Means I don’t feel the need to lie down and rest 
o Able to play with kids 
o It helps me feel stronger physically 
 After I take it – you feel it 
 Its an extra energy, a boost 
 I can walk up stairs easily 
 You don’t feel old – sometimes I do and when you take it you don’t feel that 
way 
o You can increase it if the level you’re at isn’t working 
o I can blow dry my hair 
 I’m not standing over the counter trying to blow dry my hair 
 Overall better quality of life, I can do everything I need to do 
o Can brush my teeth  
o Increases appetite 
 I don’t have a good appetite so it helps – even bread tastes so delicious. 
o Kept me stable so I can have a full time job  
 Can be in my 20s in New York, can travel and I don’t think I could do any of 
those things without it. 
o Can travel 
 Even if I don’t take it for 10 years, if I travel I know it’s with me. Makes me 
feel secure 
o Allows me to live the life I want 
 It keeps me alive 
12 
C. Works fast: It works very quickly 8 
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 My foot will be swollen and 20 minutes after taking it I can get up 
o Helps with the flare up  
E. Controls disease: Can move 
o Able to walk  
 I was bed ridden and I took the steroids and was able to walk the next day. 
It was everything – the pain and weakness. I couldn’t walk and I didn’t know 
why and once I was diagnosed and prescribed prednisone I was able to walk 
the next day 
4 
 Energy: More energy 
 Energy 
 Can get through the day 
 Gives you a burst of energy, without it you can’t go about your normal 
activities of the day, brushing your teeth or drying your hair 
 Means I don’t feel the need to lie down and rest. 
 Improves fatigue 
 It helps me feel stronger physically 
 After I take it – you feel it  
 Its an extra energy, a boost 
 I can walk up stairs easily 
 You don’t feel old – sometimes I do and when you take it you don’t feel that 
way 
2 
D. Flexibility for use: Can always get back on it – always there for an option 
 Not always a happy option, but it’s there for emergencies 
o Available just in case 
 Gives security 
 Flexibility 
 Allows you to control the pain 
1 
D. Flexibility for use: Can take it when your pregnant 
 During my second pregnancy I was very paranoid to take it while I was 
pregnant 
1 
NG #5: 5/9/2019, 4:30PM. 3 females. 1 white, 1 African American, 1 Asian. 18 votes. 
E. Controls disease: Will control disease 
 It’s the only thing that makes me happy  - taking steroids. You’re 
comforted that you will get better 
8 
E. Controls disease: Makes you feel better 
o Makes me good to go  
o Helps me function 
 It’s bad but I do rely on it more because the meloxicam is there everyday. It’s 
bad but its good too and I’ve been on it since 2003 or 2004 
3 
E. Controls disease: Helps with morning stiffness 3 
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A. Pain relief: Helps pain 
o Pain relief  
 Last January I started 60 mg and have 5 infusions. Now I’m taking half and 
I’m really hoping to get off of it because the side effects were awful 
 I needed to connect with my PCP and try to get off steroids.  
2 
D. Flexibility for use: Able to self manage dose 
 I just didn’t want to take it anymore and didn’t have any side effects or 
anything. I haven’t been on it in 10 years 
 Every time I try to go down to 1 mg, every time I try to go off of it its been a 
problem and difficult. Every time I tried to go down I had to come back up 
– I’m at 5 and I want to get off the 5 
 Once you’re on a higher dose you can’t stop taking it. I was on 5 mg and 
from there I started to cut it out 
1 
D. Flexibility for use: Can take for short period/do not have to take forever 1 
Total: 126 votes 
*9 of the 12 votes within NG1 were not applicable to the first question and were grouped 
under the other domain. 
NG = nominal group; PCP = primary care physician. 







Appendix Table 2. Responses to Question 2 “What do you think are the most 
significant unwanted effects or harm from taking steroids?” 
 
NG #1: 4/9/2019 3:00 PM. 2 Female. 1 African-American 1 White. 12 votes.  
C. Physical appearance: Changes in physical appearance 
 Would be a big issue for everyone. You can hide the stuff that’s going on 
the inside, when it starts to manifest in your physical appearance its 
harder to hide.  
o Weight gain 
 People ask me if I’m expecting again – always goes to mid section of body 
4 
B. Bone loss: Issues between bone density loss and possible AVN. 
 Impacts how you work, livelihood and social life. If you have small 
children and they want to play etc. you’re left out. You feel like you can’t be 
there for them 
o Bone density 
 Having to take calcium pills – they’re huge but you know why you’re taking 
it. 
3 
D. Damaged organs: Stomach distress 
 Helped or increases distress – it still affects your stomach 
2 
E. Infection: Increase risk of infections 
 I stay clear of people who I view are sick. It helps with other treatments 
and avoiding being sick 
 My daughter got sick, the next day I was throwing up and then had to go to 
the hospital 
 Don’t pick up a lot of colds, but do pick up weird side effects/allergies 
2 
I. Dependence: Can’t stop taking it suddenly 
 You cant decide going from 100 mg to 0 mg tomorrow. Effects of suddenly 
stopping it is very risky 
1 
NG #2: 4/10/2019, 4:30 PM. 2 Female, 1 Male. 3 African American. 18 votes. 
B. Bone loss: Loss of bone (and brittleness) 
 I did bone density scan and they told me the bone density was getting 
lower and lower – but I never had a fracture or a break 
o Bones get brittle 
 I was on crutches for a year because I was much heavier and the doctor 
told me to lose weight and I had necrosis of my left hip – it was really 
painful 
 I taught myself to walk without crutches because it wasn’t cute 
 I’m not a big fan of going under the knife; I’m scared to have the surgery  
 I have no cartilage in my hip anymore 
7 
A. Weight gain: 
 Easier for your bones to break if you gain a lot of weight 
 I went up to a size 12 so I know 
2 
F. Eye problems: Trouble with vision 




D. Damaged organs: Internal damage that it does to your organs 
 Occurs with long-term use 
 Kidneys were damaged. They gave me steroids when I had kidney 
disease before I had chemotherapy 
 It messes up your organs but then they give it to you to treat disease – 
it’s a bit confusing 
 When I was younger I had a lot of organs messed up from steroids and 
I was on it for years and it caused me to have erythema multiple forms 
– started inside and then it caused the scarring 
8 
NG #3: 4/29/2019, 4 PM. 6 females. 2 white, 2 African American, 2 Asian. 36 votes. 
A. Weight gain: 
 That really bothers me 
 It’s like an emotional roller coaster 
9 
B. Bone loss: Damage to bone 
 Spine collapsing, had to quit work because pain in my legs was 
horrendous and I couldn’t go upstairs 
o Bone density loss 
 Every time I’m on it my bone density goes lower, we always measure it and 
it’s a concern. I’ve been on and off steroids since I was young 
o Fractures 
8 
J. Weakness: Weakness in ligaments  
 Feel weaker and unstable, legs feel like sticks. They feel weaker and they’ll 
loosen when I go out 
o Tendon damage 
 I blew out my Achilles tendon and the pain kept me up for 6 months 
 Get instability mostly in hips – my heel starting bothering me and I was just 
crossing the street and fell and I didn’t know why 
 Because of the steroids I had to elevate my legs in bed for 3 months because 
they didn’t want my skin to swell because my skin became very thin. It was 
crazy 
4 
E. Infection: Lowers immune system 
o Frequent infections 
 Jumped between UTI and yeast infections 
 I have chronic bronchitis and pulmonary issues 
o Infections 
4 
G. Sleep disturbance: Lack of sleep  
 When I’m on high doses of steroids, I get so hungry I need to wake up and 
eat every 3 hours. It wakes me up because my stomach is grumbling 
2 
J. Weakness: Muscle weakness 
 Was crossing the street and my leg just went out 
o Lack of strength  
 I fell off the toilet and couldn’t get off the floor so I had to call my doorman 




K. Other: High sugar 2 
D. Damaged organs: Bloating 
o Stomach irritation  
 I cannot sleep flat; it causes a lot of stomach problems 
 When you have to take something for your damaged organs. Steroids 
adversely affects your bones 
o Stomach problems 
2 
K. Other: Skin becomes very thin 
 It’s very easy to break and when it does it won’t heal 
1 
C. Physical appearance: My face – along with weight gain; moon face 
 When I go to church, they see me weekly, not every day and people will 
say oh your face looks puffy and it gets to me 
o Puffy face 
o Round face 
1 
K. Other: High cholesterol, high sugar, high blood pressure 
 Had to take Lipitor and all that 
1 
NG #4: 5/7/2019, 4:30PM. 7 females. 2 white, 3 African American, 2 Asian. 42 votes. 
B. Bone loss: Bad for osteoporosis 
 I have osteoporosis 
o Bone loss/bone damage 
 For me it’s AVN. I’m 27 and I’m asking why do I have this and its because I’ve 
been taking it for 10 years. And I go to the gym a lot so what’s going to 
happen at 65 
 I had to have a double hip replacement 
 That’s what makes me not want to take it – it’s supposed to make me feel 
better, but its also destroying my bones 
o AVN and resulting impact on walking 
 Can’t go to the gym 
 I can’t do anything on that leg 
 Confusing because with AVN its painful but I’m told to workout everyday 
 For a long time I couldn’t move and for years I was on crutches 
17 
H. Psychological: Causes depression, mood instability 
 When I first started taking it caused mood instability – I started taking it 
when I was young and I didn’t realize it was medicine that was causing 
mood instability so I went on mood stabilizers. I always thought it was me; 
but then I realized it was the steroids. It’s a big one 
 It makes you angry 
o Angry 
o Irritability 
 Steroids make me feel like I’m going crazy, because my mom would always 
ask me why are you angry and I would just say because I am I don’t know 
o Bad mood 
o Lack of concentration 





 Sometimes I get really anxious 
 Sometimes you don’t know if its disease activity or medicine 
I. Dependence 
o Addictive 
o Dangerous to just stop you have to wean off of it 
o Instability to taper 
 Without some sort of adrenal crash or steroid fatigue 
 Takes a long time to taper 
 I was taking up to 80 mg 
8 
A. Weight gain: 
 First time I was sick and started taking I went up to 155 pounds from 140 
– it happened really fast 
o Moon face 
o Causes an increase of appetite/over eating 
3 
K. Other: Teeth problems: cavities 
 I take good care of my teeth but the steroids can eat away at your teeth. I 
didn’t know it until they told me. I had to pay for a crown and if I didn’t 
have any money I’d just not have a tooth 
2 
G. Sleep disturbance: Steroid fatigue 
 With myositis, whatever blood test they do, I was stable and my numbers 
were going down but I was still so tired. My rheumatologist said that 
there’s this thing called steroid fatigue and that it can have that kind of 
effect on your body and that was when I was on a higher dose 
2 
H. Psychological: Uncomfortable with myself 
 Shaky, on edge – my regular doctor put me on 20 mg for strep throat. And 
I didn’t want to take it. One time I just took 20 mg and he told me to take 
another one in the afternoon and I felt so bad. I was shaking, especially for 
strep throat I could have survived through it – will never do it again 
 Thought I was the only person who understood. I was going through it by 
myself – thought it was just me 
1 
K. Other: Compatibility with other drugs 1 
NG #5: 5/9/2019, 4:30PM. 3 females, 2 white, 1 African American. 18 votes. 
F. Eye Problems: Eyes  
o It effects your eyes 
 If you have problems being on prednisone it is really not a good thing. When 
I went to a lower dosage the pressure in my eyes grew. If I go to a high dose 
and stay on it the pressure goes up. It’s not glaucoma yet 
o Glaucoma 
 Didn’t change with lower doses. 
 My doctors told me that if the steroids had that effect on me than I would 
have gotten it anyways 
3 
H. Psychological: Mental stress 




 Your social life gets affected by it. You’re not able to make friends because 
of steroid side effects. I don’t have a lot of friends in my life because 
steroids might be the main cause and I do blame steroids for it 
 My height and weight gain makes you not look good, not look pretty. Your 
self-image goes down. I missed out on my social life because of it took 
steroids from age 4 to 18 
 Mental stress makes you not a normal person  
B. Bone loss: 
 Need to take calcium 
3 
K. Other: Height  
 I was 4 when I started taking the steroids and now I’m 25. It’s the main 
thing that has affected my life 
2 
G. Sleep disturbance: Fatigue 
 In my life I had school, college and doctors that’s it I had to focus more on 
my studies than a regular person. It was hard for me to focus on stuff so it 
took me longer to study.  
2 
C. Physical appearance: Hirsutism (hair growth)  
 I got a mustache and what started to look like a beard and I really want my 
mustache to go away. My doctor had to take me off because I was getting 
too many side effects 
2 
A. Weight gain: 
o Hard to lose weight 
1 
A. Weight gain: Increases appetite. 
 Even when you just ate something you think, I just ate something I 
shouldn’t be hungry and sometimes I’m just snacking and I know I’m not 
hungry. At some point I need to find a medium here. It put weight on me 
and trying to get the weight off is crazy 
 I was young when I was taking them and my mom would prepare food for 
me and I would ask for more. It took me 8 years to take the weight off 
 I have to do therapy to function. Even when I’m in therapy I think what am 
I going to eat 
 It makes you eat and you’re thinking about eating all the time 
 Compulsive eating – I had to use gum to control my appetite 
 It requires you to eat a lot of sweet stuff 
o Always thinking about food/eating 
o Eating while not hungry 
 People in my old support group would say that the appetite didn’t affect 
them, but it affected me 
 Prednisone can be your good friend and your bad friend 
1 
K. Other: Hard to study/concentrate 
o Effects your memory 
 It’s called the lupus fog and you’re talking and then forget what you’re 
saying 




for having the disability label and I needed to go back to college and 
wanted to go back and get my masters and when I went off the meloxicam 
I was able to focus 
Total: 126 votes 
NG = Nominal group. AVN = Avascular necrosis.  
A = Weight gain; B = Bone loss; C = Physical appearance; D = Damaged organs; E = Infection; F = 
Eye Problems; G = Sleep disturbance; H = Psychological Effects; I = Dependence; J = Weakness; K 
= Other 
 
 
 
 
 
